Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PHVS 
Pharvaris BV (PHVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: PHVS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $45.9
1 Year Target Price $45.9
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.89% | Avg. Invested days 38 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio - | 1Y Target Price 45.9 |
Price to earnings Ratio - | 1Y Target Price 45.9 | ||
Volume (30-day avg) 9 | Beta -2.8 | 52 Weeks Range 11.51 - 29.80 | Updated Date 12/10/2025 |
52 Weeks Range 11.51 - 29.80 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.38 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.6755 | Actual -0.6 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.07% | Return on Equity (TTM) -53.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1179010569 | Price to Sales(TTM) - |
Enterprise Value 1179010569 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 64959454 | Shares Floating 33470359 |
Shares Outstanding 64959454 | Shares Floating 33470359 | ||
Percent Insiders 5.32 | Percent Institutions 96.1 |
Upturn AI SWOT
Pharvaris BV
Company Overview
History and Background
Pharvaris BV is a biopharmaceutical company focused on developing innovative treatments for patients with rare genetic diseases. It was founded in 2021 and has quickly advanced its lead drug candidate into clinical trials. The company is privately held and has secured significant funding from venture capital firms.
Core Business Areas
- Rare Genetic Disease Therapeutics: Pharvaris BV's primary focus is on developing small molecule therapies to address the underlying causes of rare genetic diseases. Their current pipeline targets diseases with significant unmet medical needs.
Leadership and Structure
Pharvaris BV's leadership team comprises experienced professionals in drug development, clinical research, and biopharmaceutical management. The company operates with a lean and agile structure to facilitate rapid decision-making and progress in its research and development activities.
Top Products and Market Share
Key Offerings
- PHVS-045: PHVS-045 is Pharvaris BV's lead drug candidate, a novel small molecule therapeutic aimed at treating Hereditary Angioedema (HAE). Clinical trials are ongoing, and market share data is not yet available due to its early-stage development. Key competitors in the HAE market include Takeda (Takhzyro), CSL Behring (Haegarda), and BioCryst Pharmaceuticals (Orladeyo).
Market Dynamics
Industry Overview
The rare disease therapeutics market is characterized by high unmet needs, significant scientific innovation, and a favorable regulatory environment (e.g., Orphan Drug Designation). Companies in this space often focus on genetic disorders where targeted therapies can have a profound impact.
Positioning
Pharvaris BV is positioning itself as an innovator in small molecule therapeutics for rare genetic diseases, with a particular focus on HAE. Their scientific approach and pipeline advancement aim to differentiate them in a competitive landscape. They are a relatively new entrant compared to established players.
Total Addressable Market (TAM)
The global market for Hereditary Angioedema (HAE) treatments is estimated to be several billion USD and is growing. Pharvaris BV, by targeting this specific rare disease with a novel mechanism, aims to capture a significant portion of this TAM as their drug progresses through development and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- Innovative pipeline with a novel mechanism of action.
- Experienced leadership team with a track record in drug development.
- Focus on a significant unmet medical need in rare diseases.
- Strong financial backing from reputable venture capital firms.
Weaknesses
- Early-stage development, with significant clinical and regulatory hurdles remaining.
- Limited product diversification, heavily reliant on a single lead candidate.
- As a private company, limited public financial data availability.
- Relatively new entrant to the market, lacking established commercial infrastructure.
Opportunities
- Growing market for rare disease therapeutics.
- Potential for Orphan Drug Designation and market exclusivity.
- Partnership and collaboration opportunities with larger pharmaceutical companies.
- Expansion into other rare genetic diseases with similar underlying mechanisms.
Threats
- Clinical trial failures or setbacks.
- Competition from existing and emerging therapies.
- Regulatory challenges and lengthy approval processes.
- Pricing pressures and reimbursement challenges.
- Changes in the healthcare policy landscape.
Competitors and Market Share
Key Competitors
- Takeda Pharmaceutical Company (TAK)
- CSL Limited (CSLLF)
- BioCryst Pharmaceuticals, Inc. (BCRX)
Competitive Landscape
Pharvaris BV faces established competitors with existing approved therapies in the HAE market. Their advantage lies in a potentially novel mechanism of action and a focused approach. However, overcoming market leaders with established patient bases and commercial infrastructure will be challenging.
Growth Trajectory and Initiatives
Historical Growth: Pharvaris BV's growth has been characterized by rapid pipeline advancement and successful fundraising rounds since its inception in 2021.
Future Projections: Future growth is contingent on the successful progression of PHVS-045 through clinical trials and regulatory approval. Analyst projections are not yet available due to the company's private status.
Recent Initiatives: Advancement of PHVS-045 into clinical trials, securing Series B funding, and building out the scientific and operational teams.
Summary
Pharvaris BV is a promising, early-stage biopharmaceutical company targeting rare genetic diseases, particularly HAE. Its strength lies in its innovative pipeline and experienced team, supported by strong investor backing. However, it faces significant risks associated with clinical development and competition from established players. Continued success hinges on clinical trial outcomes and regulatory approvals.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases (assumed for private company information)
- Industry market reports (assumed for market size and competition)
- Venture capital funding announcements (assumed)
Disclaimers:
Information regarding privately held companies is limited and may be based on assumptions and industry knowledge. Financial data and specific market share figures are estimates or projections. This analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharvaris BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | Co-Founder, CEO & Executive Director Mr. Berndt Axel Edvard Modig CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 118 | Website https://pharvaris.com |
Full time employees 118 | Website https://pharvaris.com | ||
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.